Kazakhstan vs Papua New Guinea: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Kazakhstan
49.0%
in 2025
Papua New Guinea
44.0%
in 2025
Kazakhstan rank
156th
Papua New Guinea rank
159th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Kazakhstan
- Papua New Guinea
How they compare
Kazakhstan currently reports 49.0% against 44.0% in Papua New Guinea, a difference of 5.0%.
That makes Kazakhstan's figure about 1.1 times Papua New Guinea's.
The two have swapped places 1 time across 18 shared years of data; in 2008 it was Papua New Guinea ahead.
Kazakhstan ranks 156th and Papua New Guinea ranks 159th of 194 countries.
Kazakhstan has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Kazakhstan | Papua New Guinea | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 51.4% | 14.6% | 36.8% | Kazakhstan |
| 2020s | 50.8% | 37.8% | 13.0% | Kazakhstan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Kazakhstan or Papua New Guinea?
- Kazakhstan, at 49.0% against 44.0% in Papua New Guinea as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Kazakhstan and Papua New Guinea?
- 5.0%, with Kazakhstan ahead.
- How many years of comparable data are there for Kazakhstan and Papua New Guinea?
- 18 years are reported by both, from 2008 to 2025.
- How do Kazakhstan and Papua New Guinea rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Kazakhstan ranks 156th and Papua New Guinea ranks 159th of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.